[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100571413":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":31,"locations":37,"responsibleParty":56,"collaborators":25,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":25,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":25,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":25,"overallStatus":78,"whyStopped":25,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Al-Azhar University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Dienogest group","EXPERIMENTAL","will take 2 mg oral Dienogest",[13],"Drug: Dienogest 2 mg orally",{"label":15,"type":10,"description":16,"interventionNames":17},"Uterine artery embolization","will undergoes uterine artery embolization by local anasthesia",[18],"Procedure: UAE",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Dienogest 2 mg orally","2 mg Dienogest orally",[9],null,{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":25},"PROCEDURE","UAE","under local anasthesia uterine artery embolizationwill be done",[15],[32],{"name":33,"role":34,"phone":35,"phoneExt":25,"email":36},"AL-Azhar university Assuit","CONTACT","0882148087","Eshrq.arabi2020@gmail.com",[38],{"facility":39,"status":25,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Al Azhar university","Asyut","Assuit","71524","Egypt","EG",{"type":46,"coordinates":47},"Point",[48,49],31.18368,27.18096,{"lat":49,"lon":48},[52],{"name":53,"role":34,"phone":54,"phoneExt":25,"email":55},"Gamal mohammed Abd El Moez","201006704553+","azhararabi46@yahoo.com",{"type":57,"investigatorFullName":58,"investigatorTitle":41,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Eshraq Arabi","100571413","phase-1-ttt-of-adenomyosis-100571413",false,"NCT06719934","Ttt of Adenomyosis","Dienogest Versus Uterine Artery Embolization in Ttt of Adenomyosis -cohort Comparetive Study","Inclusion Criteria:- Age Group: 30-50 years\n\n* Women with adenomyosis\n* With or without small fibroids\n* Suffering from heavy menstrual bleeding, dysmenorrhea, and\u002For cycle- independent pain and bulk-related symptoms.\n\nExclusion Criteria:\n\n* \\- Presence of a malignancy or pelvic infection.\n* An on-going pregnancy or a desire to conceive in the future.\n* Absolute contraindication for angiography (renal impairment).\n* Chronic debilitating diseases.","FEMALE","30 Years","50 Years",{"count":70,"type":71},100,"ESTIMATED","INTERVENTIONAL",[74],"PHASE1","to evaluate use of Dienogest versus uterine arteries embolization in treatment of Adenomyosis-associated symptoms as dysmenorrhea, heavy menstrual bleeding and bulk-related symptoms",[77],"Adenomyosis","NOT_YET_RECRUITING","2024-12-02",{"date":81,"type":82},"2024-12-06","ACTUAL",{"date":84,"type":71},"2025-01-01",{"date":86,"type":71},"2026-01-01",{"name":5,"class":6},1]